2-氟-4-肼基吡啶 | 837364-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氟-4-肼基吡啶
• 英文名称: 2-fluoro-4-hydrazinopyridine
• 英文别名: 2-fluoro-4-hydrazineylpyridine；2-Fluoro-4-hydrazinylpyridine；(2-fluoropyridin-4-yl)hydrazine
• CAS: 837364-87-1
• 化学式: C₅H₆FN₃
• mdl: MFCD09029862
• 分子量: 127.121
• InChiKey: WPUCAFYQYAGPAV-UHFFFAOYSA-N

物化性质

• 熔点：
  97-99 °C(Solv: tetrahydrofuran (109-99-9); hexane (110-54-3))
• 沸点：
  277.5±25.0 °C(Predicted)
• 密度：
  1.359±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  4

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-4-hydrazinopyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-4-hydrazinopyridine
CAS number: 837364-87-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6FN3
Molecular weight: 127.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-4-肼基吡啶 在 盐酸 、 叠氮磷酸二苯酯 作用下， 以 水 、 甲苯 为溶剂， 反应 22.0h， 生成 2-(2-fluoropyridin-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one
  参考文献：
  名称：

  在 C-21 处具有新型药效团的神经活性类固醇的合成和评估可以确定具有有利 PK 谱和更高 EC50 和 Emax 的化合物作为 GABAA 受体的 PAM

  摘要：

  Zuranolone （SAGE-217） 是一种神经活性类固醇 （γ-氨基丁酸）A （GABAA） 受体阳性变构调节剂 （PAM），是 FDA 于 2023 年批准的第一个口服药物，用于治疗产后抑郁症 （PPD） 患者。SAGE-217 有一个“黑框”警告，会损害驾驶或从事其他潜在危险活动的能力。此外，SAGE-217 可引起嗜睡和意识模糊等 CNS 抑制作用、自杀念头和行为以及胚胎-胎儿毒性。基于 SAGE-217 的构效关系 （SAR），设计并合成了 28 种在 C-21 调节的 SAGE-217 衍生物下具有新型药效团的神经活性类固醇。通过突触 α1β2γ2 GABAA 受体和突触外 α4β3δ GABAA 受体细胞测定评价生物活性。最佳化合物 S28 在突触外 GABAA 受体上表现出比 SAGE-217 更有效的效力和相似的疗效。与上述不同，化合物 S28 对突触 GABAA 受体的效力与

  DOI：

  10.1016/j.ejmech.2024.116602
• 作为产物：
  描述：

  2,4,6-三氟吡啶 在 正丁基锂 、 四丁基氟化铵 、 一水合肼 、 copper(II) sulfate 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 14.17h， 生成 2-氟-4-肼基吡啶
  参考文献：
  名称：

  Regiochemically Flexible Substitutions of Di-, Tri-, and Tetrahalopyridines:  The Trialkylsilyl Trick

  摘要：

  2,4-Difluoropyridine, 2,4-dichloropyridine, 2,4,6-trifluoropyridine, 2,4,6-trichloropyridine and 2,3,4,6-tetrafluoropyridine react with standard nucleophiles exclusively at the 4-position under halogen displacement. However, the regioselectivity can be completely reversed if a trialkylsilyl group is introduced in the 5-position of the 2,4-dihalopyridines or in the 3-position of the 2,4,6-trihalopyridines or 2,3,4,6-tetrahalopyridine. Then only the halogen most remote from the bulky silyl unit (at the 2-position in the case of the 2,4-halopyridines, at the 6-position with the other substrates) gets involved in the exchange process. After removal of the silyl protective group the nucleophile is invariably found to occupy the nitrogen-neighboring position.

  DOI：

  10.1021/jo047962z

文献信息

• 단백질 인산화 효소 저해 활성을 갖는 신규한 피라졸 유도체 및 이의 용도
  申请人：Industry-University Cooperation Foundation Hanyang University ERICA Campus 한양대학교 에리카산학협력단(120120008551) Corp. No ▼ 131471-0017977BRN ▼134-82-10205

  公开号：KR20210069576A

  公开（公告）日：2021-06-11

  본 발명은 신규 피라졸 유도체 화합물, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염 및 이를 포함하는 약학적 조성물에 관한 것이다. 본 발명에 따른 피라졸 유도체 화합물은 JNK, 특히 JNK3에 대해 선택적으로 저해 활성을 나타내어 신경계 질환 (알츠하이머성 치매성 치매, 파킨슨 질환을 포함하는 퇴행성 뇌질환)의 예방 및 치료용 약학적 조성물로 이용될 수 있다.

  本发明涉及新的吡라졸衍生物化合物，其立体异构体或其药学上可接受的盐以及包含它们的药学组合物。根据本发明，吡라졸衍生物化合物表现出对JNK，特别是JNK3的选择性抑制活性，可用作预防和治疗神经系统疾病（包括阿尔茨海默病、帕金森病等退行性脑疾病）的药学组合物。
• [EN] MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS<br/>[FR] DÉRIVÉS DE SULFONYLURÉE MACROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE NLRP3
  申请人：INFLAZOME LTD

  公开号：WO2021032591A1

  公开（公告）日：2021-02-25

  The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP 3 inhibition.

  本发明涉及大环化合物，如大环磺酰脲。本发明还涉及相关的盐、溶剂合物、前药和药物组合物，以及利用这些化合物在治疗和预防医学障碍和疾病中的应用，尤其是通过NLRP 3抑制。
• Rerouting Nucleophilic Substitution from the 4-Position to the 2- or 6-Position of 2,4-Dihalopyridines and 2,4,6-Trihalopyridines: The Solution to a Long-Standing Problem
  作者：Manfred Schlosser、Thierry Rausis、Carla Bobbio

  DOI：10.1021/ol047826g

  日期：2005.1.1

  2,4-Difluoro-, 2,4,6-trifluoro-, and 2,3,4,6-tetrafluoropyridine undergo nucleophilic substitution preferentially if not exclusively at the 4-position. However, after the introduction of a trialkylsilyl group at C-3 or C-5, the halogen at the 6-(2-)position is displaced selectively. This synthetically valuable regiocontrol can also be realized with other halopyridines such as 2,4-dichloro- and 2,4,6-trichloropyridine.
• Regiochemically Flexible Substitutions of Di-, Tri-, and Tetrahalopyridines:  The Trialkylsilyl Trick
  作者：Manfred Schlosser、Carla Bobbio、Thierry Rausis

  DOI：10.1021/jo047962z

  日期：2005.4.1

  2,4-Difluoropyridine, 2,4-dichloropyridine, 2,4,6-trifluoropyridine, 2,4,6-trichloropyridine and 2,3,4,6-tetrafluoropyridine react with standard nucleophiles exclusively at the 4-position under halogen displacement. However, the regioselectivity can be completely reversed if a trialkylsilyl group is introduced in the 5-position of the 2,4-dihalopyridines or in the 3-position of the 2,4,6-trihalopyridines or 2,3,4,6-tetrahalopyridine. Then only the halogen most remote from the bulky silyl unit (at the 2-position in the case of the 2,4-halopyridines, at the 6-position with the other substrates) gets involved in the exchange process. After removal of the silyl protective group the nucleophile is invariably found to occupy the nitrogen-neighboring position.
• 10.1016/j.ejmech.2024.116602
  作者：Ma, Mingxu、Xu, Hengwei、Ye, Liang、Li, Chunmei、Zhu, Haibo、Jiang, Wanglin、Wang, Wenyan、Yang, Huijie、Yang, Yingjie、Wang, Yao、Tian, Jingwei

  DOI：10.1016/j.ejmech.2024.116602

  日期：——

  Zuranolone (SAGE-217) is a neuroactive steroid (γ-aminobutyric acid)A (GABAA) receptor positive allosteric modulator (PAM) as the first oral drug approved by the FDA in 2023, which is used to treat patients with postpartum depression (PPD). SAGE-217 has a “black box” warning with impairing ability to drive or engage in other potentially hazardous activities. In addition, SAGE-217 can cause CNS depressant

  Zuranolone （SAGE-217） 是一种神经活性类固醇 （γ-氨基丁酸）A （GABAA） 受体阳性变构调节剂 （PAM），是 FDA 于 2023 年批准的第一个口服药物，用于治疗产后抑郁症 （PPD） 患者。SAGE-217 有一个“黑框”警告，会损害驾驶或从事其他潜在危险活动的能力。此外，SAGE-217 可引起嗜睡和意识模糊等 CNS 抑制作用、自杀念头和行为以及胚胎-胎儿毒性。基于 SAGE-217 的构效关系 （SAR），设计并合成了 28 种在 C-21 调节的 SAGE-217 衍生物下具有新型药效团的神经活性类固醇。通过突触 α1β2γ2 GABAA 受体和突触外 α4β3δ GABAA 受体细胞测定评价生物活性。最佳化合物 S28 在突触外 GABAA 受体上表现出比 SAGE-217 更有效的效力和相似的疗效。与上述不同，化合物 S28 对突触 GABAA 受体的效力与